Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia.
Fiche publication
Date publication
juillet 2017
Journal
Cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Dr GUERCI-BRESLER Agnès
Tous les auteurs :
Legros L, Nicolini FE, Etienne G, Rousselot P, Rea D, Giraudier S, Guerci-Bresler A, Huguet F, Gardembas M, Escoffre M, Ianotto JC, Noël MP, Varet BR, Pagliardini T, Touitou I, Morisset S, Mahon FX,
Lien Pubmed
Résumé
Several studies have demonstrated that approximately one-half of patients with chronic myeloid leukemia (CML) who receive treatment with tyrosine kinase inhibitors (TKIs) and achieve and maintain a deep molecular response (DMR) are able to successfully discontinue therapy. In patients who have a molecular relapse, a DMR is rapidly regained upon treatment re-initiation.
Mots clés
chronic myeloid leukemia, hematology, myeloproliferative disorders, therapy discontinuation, tyrosine kinase inhibitor
Référence
Cancer. 2017 Jul;: